Aria Vaishnavi, PhD
@drariav.bsky.social
380 followers 180 following 18 posts
Assistant professor at MD Anderson Cancer Center and CPRIT scholar. Cancer biologist.
Posts Media Videos Starter Packs
Reposted by Aria Vaishnavi, PhD
oncodaily.bsky.social
International Association for the Study of Lung Cancer (IASLC) - Eric Edison Gardner Received the 2025 Young Investigator Award

@iaslc.bsky.social

oncodaily.com/career/eric-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IASLC #YoungInvestigatorAward
Eric Edison Gardner Received the 2025 Young Investigator Award - IASLC - OncoDaily
Eric Edison Gardner Received the 2025 Young Investigator Award - IASLC / 2025 Young Investigator Awardees, cancer, Eric Edison Gardner, IASLC, International
oncodaily.com
drariav.bsky.social
Hats off to superstar summer students @vskyeagle.bsky.social and Emmanuel O for fantastic rotations and presentations. So proud of you! @mdanderson.bsky.social
drariav.bsky.social
A broad group of National Institutes of Health (NIH) public servants have taken action with the "Bethesda Declaration" that targets the NIH and HHS Leadership. Join these courageous and committed professionals by adding your name now. actionnetwork.org/forms/add-na...
ADD YOUR NAME: Sign the Open Letter in Support of NIH Staff
Join the courageous and committed National Institutes of Health (NIH) public servants by adding your name now.
actionnetwork.org
drariav.bsky.social
That’s a great question! We haven’t really looked yet but could definitely explore that!
drariav.bsky.social
Collectively, this work provides evidence for an important role for ERBB family signaling in the genesis and maintenance of BRAFV600E-driven lung cancers, and the potential for future therapeutic improvement by rational combination targeting of these pathways.
drariav.bsky.social
Here, using genetic and patient-derived mouse models, we reveal that activation of BRAFV600E oncoprotein drives transcriptional upregulation of ERBB family ligands in the AT2 cells of the lung. This ERBB autocrine loop serves to support the initiation and maintenance of BRAFV600E tumors in the lung.
Reposted by Aria Vaishnavi, PhD
joachim123.bsky.social
Acc to an article in The Atlantic, Meta, using LibGen, appears to have pirated millions of articles and book chapters to train AI. The Atlantic provides a searchable link, and I find 199 of my books, book chapter, review article and major publications, all used without my permission.
www.theatlant
The Unbelievable Scale of AI’s Pirated-Books Problem
Meta pirated millions of books to train its AI. Search through them here.
www.theatlantic.com
drariav.bsky.social
Fantastic talk today by the legend herself: so great to have her in house!! Don’t mind me while I fangirl over THE Dr. Rushika Perera! @rushika-perera.bsky.social @anirbanmaitra.bsky.social
drariav.bsky.social
Save the Date! Cancer Molecular Therapeutics Research Association Annual Meeting in Utah July 13-17. Please register today. Incredible line up of speakers: RT! @andreaventura.bsky.social @rjdlab.bsky.social #lcsm
Reposted by Aria Vaishnavi, PhD
ralanharris.bsky.social
FINAL LOCATION UPDATE: Stand Up for Science 2025

The final location for Stand Up for Science on 3/7 is Jan and Dan Duncan Neurological Research Institute (NRI).

Please disregard announcements about TMC Commons.

Join us at NRI: maps.app.goo.gl/y6DbDuFMr4CK...

Looking forward to seeing you there!
drariav.bsky.social
You hit the nail on the head with this post!
Reposted by Aria Vaishnavi, PhD
ralanharris.bsky.social
Join us in Houston for Stand Up for Science 2025 on March 7 at 12:00 PM in Texas Medical Center Commons. This event is organized in solidarity with scientists nationwide. #StandUpForScience2025 #ScienceAdvocacy
Reposted by Aria Vaishnavi, PhD
jeremymberg.bsky.social
ATTENTION

If you are on a study section that was scheduled to meet, please post or DM me with information regarding:

1. The name of the study section

2. The scheduled date

3. Whether the meeting actually occurred

THANK YOU
a man wearing a top hat and a purple jacket is asking for more .
ALT: a man wearing a top hat and a purple jacket is asking for more .
media.tenor.com
Reposted by Aria Vaishnavi, PhD
alexwitze.bsky.social
Are you a scientist whose work is being affected by changes in the Trump administration? Get in touch with @nature.com reporters @maxkozlov.bsky.social @dangaristo.bsky.social @heidiledford.bsky.social Jeff Tollefson & yours truly.

Let us know what's on your mind & what we should be writing about.
Are the Trump team’s actions affecting your research? How to contact Nature
Use this form to share information with Nature’s news team, or to make suggestions for future coverage.
www.nature.com
Reposted by Aria Vaishnavi, PhD
utah.edu
A look at the economic impact of our research:

8,340 jobs created
$248m in salaries & wages paid
$328m in indirect labor income earned
$32m in state & local taxes generated

Learn more about the impact of #UofU research: www.research.utah.edu/facts-and-fi...
Graphic with the following copy: University of Utah Research
Economic Impact
768M,
689MA
The U Research Enterprise is an Engine for Economic Grown and Development
664M-
БОЗМ-
551M
In Fiscal Year 2023,
The U Hit a Historic High of
$768M
in Research Funding Awards

U of U Research
Boosts the Economy and Creates Jobs:
$248M
Research Salaries & Wages
GENERATES
$328M
Million in Indirect & Induced Labor Income
8340
Employees
$32M
In State & Local Taxes
In FY22, approximately $328 million in direct & induced labor income was generated by salaries and wages from research dollars, also generating approximately $32 million of state and local sales tax
U of U Supports Small, Local Businesses in Utah and Across the Nation
Vendor and Subaward Expenditures on Federal and Non-Federal Research Awards to University of Utah by Utah Counties (FY 2023)
$126M
7
Start-Up
Companies
囚
$28M
Technical Innovation
135
Patents Issued
Utah Expenditures
$361,000 to $22,700,000
$106,000 to $361,000
$27,200 to $106,000
$3,900 to $27,200
$40 to $3,900
28
Products Launch
Reposted by Aria Vaishnavi, PhD
bradylabupenn.bsky.social
Congratulations to @ginadenicola.bsky.social and @christhechang.bsky.social labs on their latest @pnas.org paper revealing context-dependent sensitivity to copper chelation! Thrilled to have collaborated with such amazing friends on the first manuscript of 2025.
ginadenicola.bsky.social
Our lab's first paper of 2025. With @christhechang.bsky.social we find that NRF2 active lung cancer cell lines suppress labile copper and are vulnerable to copper chelation (1/3).
christhechang.bsky.social
Activity-based sensors identify cuproplasia and ferroplasia as druggable metal vulnerabilities in cancer! With @ginadenicola.bsky.social and Adam Renslo, we profile cancer cell lines to find those sensitive to Cu or Fe chelation www.pnas.org/doi/10.1073/... www.pnas.org/doi/10.1073/... #chemsky 1/n
Reposted by Aria Vaishnavi, PhD
prasad.bsky.social
“NIH produces an astounding return on investment to the American taxpayer. In Fiscal Year 2022, NIH research funding supported 568,585 jobs and generated $96.84 billion in economic activity — that’s $2.64 of economic activity for every $1 of research funding.”
www.researchamerica.org/2023-oped-us...
crampell.bsky.social
Research supported by NIH has led more than 100 Nobel Prizes and has supported more than 99% of drugs approved by federal regulators from 2010 to 2019.
But come January, NIH may face a wrecking ball
nytimes.com/2024/12/01/h...
Long a ‘Crown Jewel’ of Government, N.I.H. Is Now a Target
nytimes.com
Reposted by Aria Vaishnavi, PhD
harmitmalik.bsky.social
My New Year’s resolution is to berate myself less for things I wish I could have done better, to learn from my mistakes, and give myself more credit for the things I did well but promptly forgot/ignored because academics love to live from crisis to crisis
drariav.bsky.social
Yes! I have a couple I can email you— one is from scratch and one is “pretty” defined but both work great for lung adenos
Reposted by Aria Vaishnavi, PhD
mdanderson.bsky.social
The FDA has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for first-line treatment in patients with metastatic colorectal cancer with a BRAF V600E mutation. The approval is based on the BREAKWATER study, for which MD Anderson’s Dr. Scott Kopetz is co-PI. 1/2
FDA grants accelerated approval
The Food and Drug Administration granted accelerated approval to encorafenib.
www.fda.gov